Salute e Benessere
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
The Phase I/II EMERALD study is a multi-centre, single-arm, first-in-human, open-label study designed to evaluate the safety and efficacy of RTX001 in patients with end-stage liver disease who have recovered from a recent hepatic decompensation. The study is being conducted at leading hepatology centres across the UK and Spain and will enrol up to 25 patients, with the first patient dosed at the Royal Infirmary of Edinburgh .
said .
The Phase I/II EMERALD study builds on promising results in the academic MATCH Phase I & II studies where non-engineered RMT was well tolerated with transformational efficacy in advanced liver cirrhosis. RTX001 has been developed as a commercial product and is engineered with IL-10 and MMP-9 to enhance the anti-inflammatory and anti-fibrotic effects of RMT to therefore enable improved patient outcomes and longevity of effect in end-stage liver disease.
Additional information on the Phase I/II EMERALD study can be found on , NCT identifier .
Resolution Therapeutics has a pipeline of innovative programs developing RMT for additional fibrotic and inflammatory diseases with significant commercial opportunity, with an initial focus on Graft-versus-Host Disease (GvHD) and lung fibrosis.
Resolution is hosting an R&D Webinar on Wednesday 17 September 2025 at 2pm BST / 9am ET / 6am PT alongside world leading clinical hepatologists Professor Jonathan Fallowfield , Chair of Translational Liver Research and Principal Investigator at the University of Edinburgh , Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh , and Dr. Elliot Tapper , MD, FAASLD, Andrews Family Research Professor of Hepatology and Associate Professor of Internal Medicine at the University of Michigan Medical School.
Please use the following link to register. A replay will be available on the News page of the Resolution Website following the event's completion.
RTX001 is an engineered autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effects. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is being tested in the Phase I/II study called 'EMERALD', an open-label first-in-human study in end-stage liver disease measuring clinical events as the primary efficacy endpoint. The EMERALD Phase I/II study is now recruiting.
Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution's initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh , is based in Edinburgh and London . Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.
View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-announces-first-patient-dosed-in-phase-iii-emerald-study-of-rtx001-for-the-treatment-of-end-stage-liver-disease-302544026.html